Epstein-Barr virus infections is a disease associated with the glandular fever and usually occurs in the childhood. The symptoms associated with the disease include fever, fatigue, lack of appetite, sore throat, swollen glands and weakness. The virus is found in the saliva, blood and semen and can spread through kissing an infected person, using infected person’s toothbrush, blood transfusion and organ transplant. The disease can be prevented by not sharing drinks, food, or personal items; such as toothbrushes, with people who have EBV infection. ViraCyte, LLC is in the process of developing Viralym-M for the treatment of Epstein-Barr virus infections. The drug candidate is being developed as a T-lymphocyte replacement for the treatment of different viral infections simultaneously. Some of the companies having a pipeline of Epstein-Barr virus infections include Genocea Biosciences, Inc., Vironika, LLC and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities, including information about clinical results, designations, collaborations, licencing, grants, technology and others.